| Therapeutic Efficacy of Gliptide (Sulglycotide 200 mg): A Double Blinded, Randomized, Active Drug Comparative, Multicenter Study |
|
Jeong Seop Moon, Soo Heon Park, Jong Jae Park, Sang Woo Lee, Dong Ho Lee, Yong Chan Lee, Hwoon Yong Jung, Jae Gyu Kim, Oh Young Lee, Jae J Kim |
1Department of Internal Medicine, Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea.
2Department of Internal Medicine, Yeouido St. Mary's Hospital, The Catholic University of Korea, College of Medicine, Seoul, Korea.
3Department of Internal Medicine, Guro Hospital, Korea University College of Medicine, Seoul, Korea.
4Department of Internal Medicine, Ansan Hospital, Korea University College of Medicine, Ansan, Korea.
5Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
6Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
7Department of Internal Medicine, Ulsan University College of Medicine, Asan Medical Center, Seoul, Korea.
8Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
9Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.
10Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University College of Medicine, Seoul, Korea. jjkim@skku.edu |
| 위염환자에서 글립타이드 정(Sulglycotide 200 mg)의 치료 효과: 이중 눈가림, 무작위 배정, 비교약 대조, 다기관 임상시험 |
|
문정섭, 박수헌1, 박종재2, 이상우3, 이동호4, 이용찬5, 정훈용6, 김재규7, 이오영8, 김재준9 |
|
인제대학교 의과대학 서울백병원 내과학교실, 가톨릭대학교 의과대학 여의도성모병원 내과학교실1, 고려대학교 의과대학 구로병원 내과학교실2, 고려대학교 의과대학 안산병원 내과학교실3, 서울대학교 의과대학 분당서울대학교병원 내과학교실4, 연세대학교 의과대학 세브란스병원 내과학교실5, 울산대학교 의과대학 서울아산병원 내과학교실6, 중앙대학교 의과대학 내과학교실7, 한양대학교 의과대학 내과학교실8, 성균관대학교 의과대학 삼성서울병원 내과학교실9 |
|
|
| Abstract |
BACKGROUND/AIMS
Sulglycotide is a non-systemic drug, used in the treatment of peptic ulcer and gastritis. The aim of this study was to assess the therapeutic effect and safety of Gliptide (sulglycotide 200 mg) in comparison with Mucosta (rebamipide 100 mg) for treatment of gastritis. MATERIALS AND METHODS: Two hundred and three symptomatic patients with erosive gastritis at endoscopy were randomized to receive sulglycotide or rebamipide for four weeks. Therapeutic effects of the drugs for gastritis were evaluated by follow up endoscopic scoring systems and clinical symptoms. We also sought possible adverse effects of the two drugs. RESULTS: Gliptide (sulglycotide) and Mucosta (rebamipide) treatment in symptomatic gastritis resulted in endoscopic improvement rates of gastritis by 52.0%, 60.6% in intention-to-treat (ITT) analysis, 53.4%, 61.1% in per protocol (PP) analysis, which means therapeutic effects was not different between the two groups. The symptom improvement rates in the sulglycotide and rebamipide treated group were 57.3%, 57.5% in ITT analysis, 54.7%, 58.8% in PP analysis, which mean statistically no significant difference between the two groups. Endoscopic findings such as cure rates of erosion, edema, improvement rates of redness, hemorrhage were not significantly different between the two groups. No statistical significant differences were observed for adverse events between the two groups. The results of 95% CIs for the difference in endoscopic improvement rate and symptom improvement rate met the criteria for the non-inferiority of sulglycotide to rebamipide. CONCLUSIONS: These results demonstrate that Gliptide (sulglycotide) was not inferior to Mucosta (rebamipide) for endoscopic and symptomatic improvements for symptomatic erosive gastritis. |
| Key Words:
Sulglycotide; Gastritis |
|
PDF Links
Full text via DOI
Download Citation
